Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ampio Pharmaceuticals, Inc. (AMPE)

3.67   -0.062 (-1.66%) 09-27 15:42
Open: 3.68 Pre. Close: 3.7321
High: 3.825 Low: 3.649
Volume: 9,817 Market Cap: 3(M)

Technical analysis

as of: 2023-09-27 4:17:38 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 5.27     One year: 6.07
Support: Support1: 3.4    Support2: 2.82
Resistance: Resistance1: 4.51    Resistance2: 5.19
Pivot: 4.24
Moving Average: MA(5): 3.9     MA(20): 4.17
MA(100): 4.7     MA(250): 5.75
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 7.1     %D(3): 13.2
RSI: RSI(14): 40.4
52-week: High: 21  Low: 3.4
Average Vol(K): 3-Month: 35 (K)  10-Days: 46 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AMPE ] has closed above bottom band by 10.2%. Bollinger Bands are 14.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.01 - 4.05 4.05 - 4.07
Low: 3.54 - 3.59 3.59 - 3.62
Close: 3.68 - 3.76 3.76 - 3.8

Company Description

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Headline News

Tue, 26 Sep 2023
Ampio Pharmaceuticals to Present at the Emerging Growth Conference - Yahoo Finance

Tue, 12 Sep 2023
Healthcare Stocks on the Move Tuesday: AMPE, AXLA, MYO, PIII, SGHT, OFIX, CGC, AYRWF - InvestorsObserver

Thu, 31 Aug 2023
Ampio Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance

Thu, 22 Jun 2023
3 Biotech Stocks to Buy With Explosive Upside Potential - InvestorPlace

Fri, 26 May 2023
Ampio Pharmaceuticals Announces Series D Preferred Stock ... - PR Newswire

Tue, 18 Apr 2023
Ampio Pharmaceuticals Issues Letter to Stockholders - April 18, 2023 - BioSpace

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 0 (M)
% Held by Insiders 0 (%)
% Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.